Gemphire's gemcabene meets in Phase IIb for severe hypertriglyceridemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) reported data from the Phase IIb INDIGO-1 trial to treat severe hypertriglyceridemia showing that once-daily 600

Read the full 208 word article

User Sign In